molecules of the month


oral, HIV-1 IN-LEDGF/p75 allosteric inhibitor

Ph. I for FIH safety

from cell screen of INLAI library

BioRxiv, January 28, 2022

Biodim, Romainville, FR

BDM2 chemical structure oral, HIV-1 IN-LEDGF/p75 allosteric inhibitor - Biodim, Romainville, FR
4 mins read

Newly disclosed HIV-1 antiretroviral is the first integrase-LEDGF/p75 allosteric HIV-1 inhibitor to clear Ph. I safety trials. Biodim has recently disclosed a small molecule candidate, BDM-2, that demonstrates nanomolar activity against HIV-1 replication in vitro and showed promising safety in healthy subjects in a 2020 Ph. I clinical trial (NCT03634085). BDM-2 is an allosteric HIV-1 integrase (IN) inhibitor (ALLINI), a class of compounds discovered prior to 2009 by Boehringer Ingelheim (WO2009/062285A1) that have a distinct mechanism of action from other HIV antiretroviral therapies, potentially offering a route to countering HIV mutants that are resistant to existing therapies. The molecule is highly potent, with an EC50 of 8.7 nM  for HIV-1 NL4-3 inhibition in MT4 cells (via HTFR), exceeding that of…

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: